POST LEONARD E 4
4 · CG Oncology, Inc. · Filed Nov 18, 2025
Insider Transaction Report
Form 4
POST LEONARD E
Director
Transactions
- Exercise/Conversion
Common Stock
2025-11-17$0.60/sh+1,000$600→ 1,000 total - Exercise/Conversion
Director Stock Option (right to buy)
2025-11-17−1,000→ 117,077 totalExercise: $0.60Exp: 2028-07-08→ Common Stock (1,000 underlying) - Sale
Common Stock
2025-11-17$41.43/sh−1,000$41,430→ 0 total
Footnotes (2)
- [F1]The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024.
- [F2]Fully vested